Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07525141 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-1761981 in Participants With Solid Tumors
A Phase 1 study, sponsored by Johnson & Johnson Enterprise Innovation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT07525141 is a Phase 1 study that is actively recruiting participants, run by Johnson & Johnson Enterprise Innovation. The registered enrollment target is 66 participants.
The verdict
NCT07525141, a Phase 1 study, is actively recruiting participants, sponsored by Johnson & Johnson Enterprise Innovation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Interventions
- DRUG Cetrelimab
- DRUG JNJ-1761981
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2029-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07525141
The ClinicalTrials.gov registry entry for NCT07525141 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Enterprise Innovation, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cetrelimab is the first listed.
NCT07525141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07525141 about?
NCT07525141 is a clinical study titled "A Study of JNJ-1761981 in Participants With Solid Tumors". The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
What is the current status of trial NCT07525141?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2026-05-18. Estimated completion is 2029-01-31.
What interventions are being tested in trial NCT07525141?
The interventions under investigation include: Cetrelimab (DRUG), JNJ-1761981 (DRUG).
Who is sponsoring clinical trial NCT07525141?
This trial is sponsored by Johnson & Johnson Enterprise Innovation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.